C-myb、PARP基因蛋白表达与食管癌放疗敏感性的相关因素分析

Correlation between expression of C-myb and PARP and sensitivity to radiotherapy in patients with esophageal carcinoma

目的探讨C·myb与PARP（聚腺苷二磷酸核糖聚合酶）与食管癌放疗敏感性的关系。方法将124例食管癌患者分为四组，C-myb阳性组，PARP阳性组，C-myb与PARP双阳性组和双阴性组，进行常规分割放疗，2Cy／次，5次／周，至DT60-64Cy／30～32次，未加用化疗。结果四组3年局控率分别为37．9％、34．3％、25．8％、62．0％；3年生存率分别为13．8％、14．3％、9．6％、34．5％。结论C-myb与PARP可作为预测食管癌放疗敏感性的检测手段之一。C-myb与PARP阳性者预后较差，应改变治疗模式或联合治疗。

Objective To discuss the correlation between the expression of C-myb and poly adp-ribose polymerase （PARP） genes and the sensitivity to radiotherapy in patients with esophageal carcinoma. Methods A total of 124 patients were divided into four groups, i.e. C-myb positive group, PARP positive group, C-myb and PARP positive group, C-myb and PARP negative group. All the patients were treated with radiotherapy （2Gy per day, 5 sessions a week to DT 60 -64Gy/30 -32 sessions）. Results The 3-year local control rates of the four groups were 37.9%, 34.3%, 25.8% and 62.0% ; the 3-year survival rates were 13.8% , 14.3%, 9.6% and 34.5%, respectively. Conclusion C-myb and PARP can be used as means to detection of radiotherapeutic sensitivity in the patients with esophageal carcinoma. The prognosis is bad in those with positive C-myb and PARP who needs changes in thera- peutic regimen.